secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0000950170-22-013212
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns appoints Dr. Radhika Tripuraneni to board of directors
------------------------------------------------------------

- Dr. Tripuraneni appointed as Class II director and Audit Committee member effective July 26, 2022.
- She is Chief Development Officer of Prothena Corporation plc with over 15 years of drug development experience.
- No material transaction or arrangement exists with Dr. Tripuraneni or any related party.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017022013212/0000950170-22-013212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017022013212/tern-20220726.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-013212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer